Cargando…

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

PURPOSE: Primary immunodeficiency diseases (PIDDs) are a heterogenous group of disorders characterized by intrinsic impairment in the immune system. Most patients with PIDD require life-long immunoglobulin G replacement therapy, which has been shown to reduce the rate of infections and, related hosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallick, Rajiv, Jolles, Stephen, Kanegane, Hirokazu, Agbor-Tarh, Dominique, Rojavin, Mikhail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292975/ https://www.ncbi.nlm.nih.gov/pubmed/30465179 http://dx.doi.org/10.1007/s10875-018-0562-3

Ejemplares similares

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
por: Jolles, Stephen, et al.
Publicado: (2018)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age
por: Patel, Niraj C., et al.
Publicado: (2015)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
por: Sidhu, Jagdev, et al.
Publicado: (2014)

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)
por: Vultaggio, Alessandra, et al.
Publicado: (2018)

Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
por: Patel, Niraj C., et al.
Publicado: (2023)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial
por: Viallard, J. F., et al.
Publicado: (2016)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes
por: Mallick, Rajiv, et al.
Publicado: (2022)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment
por: Eltan, Sevgi Bilgic, et al.
Publicado: (2022)

Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies
por: Shabaninejad, Hosein, et al.
Publicado: (2017)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
por: Mallick, R., et al.
Publicado: (2020)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
por: Epland, Kristin, et al.
Publicado: (2022)

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
por: Grigoriadou, S, et al.
Publicado: (2022)

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency
por: Berger, Melvin
Publicado: (2008)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Editorial: Creating Awareness for Primary Immunodeficiencies in the Southeast and East Asia Regions
por: Ismail, Intan Hakimah, et al.
Publicado: (2022)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies
por: Wiesik-Szewczyk, Ewa, et al.
Publicado: (2020)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency
por: Rojavin, Mikhail A., et al.
Publicado: (2016)

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy
por: Gernez, Yael, et al.
Publicado: (2018)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)

Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
por: Fasshauer, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4977c4me91tn7uqoaophj5s01u